Biogen: raises 2021 guidance
(CercleFinance.com) - Biogen has raised its FY 2021 adjusted EPS guidance range to 18.
85-19.35 dollars (from 17.50-19 dollars) and its revenue guidance to 10.8-10.9 billion dollars (from 10.65-10.85 billion dollars).
The biopharmaceutical company reported Q3 adjusted EPS of 4.77 dollars on sales that are down 18% at 2.78 billion dollars, mainly due to lower revenues in multiple sclerosis.
The company said that it has continued to make progress in its multiple sclerosis, spinal muscular atrophy and biosimilars businesses, and is particularly encouraged by the ongoing launch of Vumerity.
The share is up over 2% in pre-market trading today.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
85-19.35 dollars (from 17.50-19 dollars) and its revenue guidance to 10.8-10.9 billion dollars (from 10.65-10.85 billion dollars).
The biopharmaceutical company reported Q3 adjusted EPS of 4.77 dollars on sales that are down 18% at 2.78 billion dollars, mainly due to lower revenues in multiple sclerosis.
The company said that it has continued to make progress in its multiple sclerosis, spinal muscular atrophy and biosimilars businesses, and is particularly encouraged by the ongoing launch of Vumerity.
The share is up over 2% in pre-market trading today.
Copyright (c) 2021 CercleFinance.com. All rights reserved.